A major international clinical trial has found that finerenone can significantly slow the loss of kidney function in people with chronic kidney disease (CKD) who do not have diabetes. The findings suggest the drug could become an important new treatment option for a large group of patients who have historically had limited therapies beyond standard care.
The research was led by clinical pharmacologist Hiddo Lambers Heerspink of the University Medical Center Groningen and published in the New England Journal of Medicine.
Large International Trial Evaluates Finerenone
The FIND-CKD study enrolled 1,584 adults with chronic kidney disease and followed them for an average of just over three years. Every participant had impaired kidney function along with elevated levels of protein in the urine, which is a key warning sign that kidney damage may continue to worsen.
Participants were randomly assigned to receive either a daily dose of finerenone or a placebo. Both groups also continued receiving standard treatment with ACE inhibitors or angiotensin receptor blockers.
